Navigation Links
Abilify Has Made Strong Gains in Patient Share Across All Lines of Therapy Since Last Year's Analysis of Prescribing Trends in Schizophrenia
Date:7/23/2009

WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. Abilify is second to risperidone (Janssen's Risperdal, generics) in first and second lines of therapy and leads other atypicals in the third line.

"Abilify's first-line patient share grew from 4.2 percent in our 2008 analysis to 14.6 percent in the current dataset. Pfizer's Geodon also grew substantially compared with our 2008 analysis whereas both Eli Lilly's Zyprexa and AstraZeneca's Seroquel lost first-line patient share," stated Nicole Westphal, Ph.D., analyst at Decision Resources. "These data suggest that Abilify and Geodon's better penetration of first-line therapy came at the expense of others in the class and we attribute Zyprexa's and Seroquel's declining use across early lines of therapy to concerns about their metabolic side effects."

The new Treatment Algorithms in Schizophrenia report also finds that surveyed psychiatrists will remain focused on an agent's metabolic or weight gain side effects when treating current and newly diagnosed patients. The majority of surveyed psychiatrists will switch patients from atypicals with unfavorable metabolic side-effect profiles to those with more favorable profiles or increasingly consider weight gain and metabolic side-effect profiles when choosing an antipsychotic in the first-line.

By combining patient-level claims data with physician survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models.

Patient-flow analysis for Janssen's Invega shows that only three perce
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
2. ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old
3. FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD
4. ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
5. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
6. US FDA approves ABILIFY for adolescent patients with schizophrenia
7. Quest Diagnostics Reports Strong Performance in Second Quarter 2009
8. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
9. Minority Business Accelerator 2.5+ Client Strong Tool Lands Multimillion Dollar Deal With GE Healthcare
10. TeamPraxis Finishes Strong First Year of National Sales
11. Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Shanghai, China (PRWEB) December 22, 2014 ... for MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma ... Health , a leading global healthcare consulting firm. MabThera ... B-cell lymphoma (DLBCL), the most common form of NHL. ... Market Access and Barriers,” the incidence of NHL in ...
(Date:12/22/2014)... Give a loved one the greatest ... health and vitality. , For a limited time, HealthiPlus ... formulas in special Holiday Wellness gift packages at drastically ... Each bottle contains cutting-edge, proven nutritional support for joints, ... well as we age. , Joint Health ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... December 22, 2014 NAPW ... Professional Woman of the Year. She is recognized with ... largest, most recognized networking organization of professional women in ... National Association of Professional Women is a vibrant networking ... Chapters. , Ms. Kreider is passionate and committed to ...
(Date:12/21/2014)... 2014 In this report, the ... power source, product, and application. The market, by ... pneumatic instruments. By product, the market covers the ... The handpieces market is further subdivided into drills, ... laparoscopic instruments, shavers, wire/pin drivers, and others. Moreover, ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Australian-based,natural health care products company that markets a range ... nature identical ingredients,announced today that its Quit Nits head ... United States through a distribution agreement with,CVS Pharmacies., ... agreement was the,result of two years of hard work ...
... identified a gene that is the key switch that ... , Much like students in a kindergarten class lining ... is identified as Smarcd3, must align correctly with two ... known as myogenesis, said principal investigator Monte Westerfield, a ...
... is a company with a renowned track record ... high throughput technologies. Genomatix algorithms include optimized fast ... complete genome annotation in terms of transcriptome and ... databases in this specific content by a factor ...
... of us probably don,t think much,about being regular, ... Johanson,practicing gastroenterologist at the Beloit Clinic in Beloit, ... health is that we,re,not getting enough fiber., ... http://media.medialink.com/WebNR.aspx?story=34435 Registered journalists can access video, ...
... the top killers in the country, but youd never know it ... of the Society for Critical Care Medicine (SCCM). , Research ... blood pressure, yet many of them dont even know it. ... the medications they need to control it," says Dr. Christopher Granger, ...
... improves access by ... care facilities and consumers, BUFFALO, N.Y., Jan. ... health care provider network to provide,routine wellness and ... the company announced today., HealthTransaction Network connects ...
Cached Medicine News:Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 3Health News:Oregon researchers find trigger gene for muscle development 2Health News:Severe hypertension: 'Silent killer' still on the loose 2Health News:Buffalo Company Launches First-ever National Electronic Transaction Network to Improve Health Care Access for Uninsured and Underinsured 2Health News:Buffalo Company Launches First-ever National Electronic Transaction Network to Improve Health Care Access for Uninsured and Underinsured 3
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... YORK , Dec. 22, 2014  Relmada ... novel therapies for the treatment of chronic pain, ... has been dosed in a pharmacokinetic and pharmacodynamic ... antagonist for neuropathic pain. Racemic methadone ... of various pain states and substitution therapy in ...
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... Reportlinker.com announces that a new market research report ... The U.S. Medical Laboratories Industry - 10th Edition ... best-selling Marketdata study is a comprehensive analysis of the ... business. The industry was hurt by the recession but ...
... (Nasdaq: OREX ) announced today the upcoming resignation ... Mr. Cooper, who has been with Orexigen for over four ...  He has been commuting from the San Francisco Bay Area ... remain in his current role at Orexigen until the reporting ...
Cached Medicine Technology:Reportlinker Adds The U.S. Medical Laboratories Industry - 10th Edition 2Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 2Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: